Vall d’Hebron University Hospital (HUVH) has signed an agreement with "http://www.bms.es/Pages/Home.aspx" Bristol-Myers Squibb (BMS) to become one of its preferred investigation sites to support its clinical trial book of work. This is a collaboration of mutual respect for the complementary skills of each organization, and will be driven by an alignment in goals to support drug development. This partnership demonstrates core principles of innovation, transparency and a commitment to quality, strong performance and continuous improvement.BMS is a Biopharma Company committed to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. They commit to scientific excellence and investment in biopharmaceutical research and development to provide innovative, high-quality medicines that address the unmet medical needs of patients with serious diseases. BMS is signing agreements with the best investigational sites. HUVH, the biggest hospital of Catalonia, is the leader of clinical trials in Spain, a reference in biomedicine research, and is signing preferential agreements with the best Biopharma Companies.